Merck’s (NYSE: MRK) Q3 2026 results reflect continued strength in oncology and animal health, plus contributions from other products in our broader portfolio. Our company announced Q3 worldwide sales of $18.1 billion.
“Our science-led strategy is transforming our business,” said Rob Davis, chairman and CEO. “The potentially practice-changing advances in oncology research presented at the ESMO Congress 2026 further clinically de-risk the substantial long-term opportunity of our late-phase pipeline. With positive momentum across multiple therapeutic areas, I’m increasingly confident in our ability to deliver long-term value for patients and shareholders.”
Merck anticipates full-year 2026 worldwide sales to be between $66.8 billion and $67.3 billion.
Take a look at the infographic below for more details on Q3 2026 results.
